<DOC>
	<DOCNO>NCT00003118</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether surgery effective without chemotherapy radiation therapy cancer esophagus . PURPOSE : Randomized phase III trial compare effectiveness surgery without combination chemotherapy radiation therapy treat patient cancer esophagus surgically remove .</brief_summary>
	<brief_title>Surgery With Without Chemotherapy Radiation Therapy Treating Patients With Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall five-year survival rate treatment failures patient receive neoadjuvant cisplatin ( CDDP ) plus fluorouracil ( 5-FU ) concomitant radiotherapy follow surgical resection versus patient receive surgery alone . II . Assess compare toxicity approach . III . Compare incidence pattern local ( gastric esophageal bed regional lymph node ) distant ( supraclavicular lymph node , liver , peritoneal carcinomatosis , lung , brain , etc . ) recurrence . IV . Evaluate prognostic ability noninvasive minimally invasive pretreatment stag regard survival recurrence . V. Evaluate ability preresection adjuvant chemotherapy concomitant radiation therapy render tumor low stage . VI . Evaluate impact lymph node survival recurrence . OUTLINE : This two arm , randomize study . Patients stratify : cell type cancer ( squamous cell v adenocarcinoma ) ; lymph node ( positive v negative ) ; stage ( invasive v noninvasive ) . Patients arm I undergo chemotherapy radiotherapy within 24 hour . Chemotherapy consist cisplatin ( CDDP ) bolus IV infusion 30 minute day 1 day 29 . Fluorouracil ( 5-FU ) administer continuous IV infusion 4 day ( day 1-4 29-32 ) completion cisplatin . Radiotherapy administer day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , boost day 36-38 . If disease progression unresectable disease , surgery perform within 3-8 week follow completion therapy . Patients arm II undergo surgery alone later 6 week postrandomization . Patients follow least every 3 month two year , every 6 month next two year , annually thereafter .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients histologically document untreated squamous cell carcinoma adenocarcinoma thoracic esophagus ( 20 cm ) gastroesophageal junction le 2 cm distal spread gastric cardia eligible . 2 . No evidence distant metastatic disease history physical examination 3 . Upper endoscopy biopsy , compute tomography ( CT ) chest upper abdomen , pulmonary function study require . 4 . Bone scan require alkaline phosphatase 3X institutional normal value . 5 . Bronchoscopy required primary tumor adjacent trachea leave main stem bronchus . 6 . Patients require : granulocyte count ≥1,800/mL platelet count ≥ 100,000/mL creatinine clearance ≥ 50 mL/min 7 . Esophageal ultrasound ( EUS ) preresection stag thoracoscopy ( t ) laparoscopy/minilaparotomy ( l ) , include biopsy celiac axis less curvature recommend 8 . Tumors must consider surgically resectable ( T13 , NX ) , include regional thoracic lymph node ( N1 ) metastases . 9 . Patients supraclavicular lymph node measure ≤ 1.5 cm CT ( palpable ) eligible . 10 . Patients lymph node metastasis level 15 20 ( predominantly celiac axis paracardial node ) ≤1.5 cm CT. 11 . Patients may previously receive chemotherapy radiation therapy tumor radiation therapy would overlap radiation field require malignancy . 12 . Patients previous malignancy eligible 5 year elapse diagnosis without evidence tumor recurrence . 13 . There serious illness would limit survival less 2 year , psychiatric condition would prevent compliance treatment informed consent . Patients uncontrolled severe cardio vascular disease , pulmonary disease , oractive infection exclude . 14 . Pregnant patient exclude . 15 . Informed consent require patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>